Netrin-1 blockade inhibits tumour growth and EMT features in endometrial cancer | Nature
We describe netrin-1 upregulation in a majority of human endometrial carcinomas and demonstrate that netrin-1 blockade, using the anti-netrin-1 antibody NP137, is effective both in a mouse model and in patients with endometrial carcinomas.
Download PDF Subjects Endometrial cancer Translational research Tumour heterogeneity Abstract Netrin-1 is upregulated in cancers as a protumoural mechanism 1 . Here we describe netrin-1 upregulation in a majority of human endometrial carcinomas (ECs) and demonstrate that netrin-1 blockade, using an anti-netrin-1 antibody (NP137), is effective in reduction of tumour progression in an EC mouse model. We next examined the efficacy of NP137, as a first-in-class single agent, in a Phase I trial comprising 14 patients with advanced EC. As best response we observed 8 stable disease (8 out of 14, 57.1
Explore this link on the map →related reading
- Cancer cells educate natural killer cells to a metastasis-promoting cell state - PMCpmc.ncbi.nlm.nih.gov
- Cancer cells educate natural killer cells to a metastasis-promoting cell state - PubMedpubmed.ncbi.nlm.nih.gov
- Research advances in treatment strategies for breast cancer liver metastases: A comprehensive review - PMCpmc.ncbi.nlm.nih.gov
- Nasopharyngeal Carcinoma(Archived) - StatPearls - NCBI Bookshelfncbi.nlm.nih.gov
- UpToDateuptodate.com
- Targeting telomerase for cancer therapy | Oncogenenature.com
- UpToDateuptodate.com
- UpToDateuptodate.com
- Enteromeenterome.com
- The blood cancer that became solvableworksinprogress.news
- The novel mechanism of lenalidomide activity - PMCncbi.nlm.nih.gov
- Immunotherapy in pediatric malignancies: current status and future perspectives - PMCncbi.nlm.nih.gov